Synergistic impact of N-antigenemia profiled by a rapid antigen test and low anti-S1 antibodies on the risk of hospitalization in COVID-19
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Identifying patients with COVID-19 who are at risk of poor evolution is key to early decide on their hospitalization. We evaluated the combined impact of nucleocapsid (N)-antigenemia profiled by a rapid test and antibodies against the S1 subunit of the SARS-CoV S protein (S1) on the hospitalization risk of patients with COVID-19.
METHODS: N-antigenemia and anti-S1 antibodies were profiled at admission to the emergency department in 146 patients with COVID-19 using the Panbio® antigen Rapid Test and the SARS-CoV-2 immunoglobulin G II Quant/SARS-CoV-2 immunoglobulin G assay from Abbott. A multivariable analysis was used to evaluate the impact of these factors on hospitalization.
RESULTS: Patients with a positive N-antigen test in plasma and anti-S1 levels <2821 arbitrary units/mL needed hospitalization more frequently (20 of 23, 87%). A total of 20 of 71 (28.2%) of those showing a negative N-antigen test and anti-S1 ≥2821 arbitrary units/mL were hospitalized for 18 of 52 (34.6%) of the patients with only one of these conditions. Patients with a positive N-antigen test and low antibody levels showed an odds ratio, 95% confidence interval, and P-value for hospitalization of 18.21, 2.74-121.18, and 0.003, respectively, and exhibited the highest mortality (30.4%).
CONCLUSIONS: Simultaneous profiling of a rapid N-antigen test in plasma and anti-S1 levels could help to early identify patients with COVID-19 needing hospitalization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:140 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 140(2024) vom: 10. Feb., Seite 132-135 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de la Fuente, Amanda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-S1 antibodies |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 23.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2024.01.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368005291 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368005291 | ||
| 003 | DE-627 | ||
| 005 | 20240229144311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240205s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2024.01.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM368005291 | ||
| 035 | |a (NLM)38311026 | ||
| 035 | |a (PII)S1201-9712(24)00019-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de la Fuente, Amanda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synergistic impact of N-antigenemia profiled by a rapid antigen test and low anti-S1 antibodies on the risk of hospitalization in COVID-19 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Identifying patients with COVID-19 who are at risk of poor evolution is key to early decide on their hospitalization. We evaluated the combined impact of nucleocapsid (N)-antigenemia profiled by a rapid test and antibodies against the S1 subunit of the SARS-CoV S protein (S1) on the hospitalization risk of patients with COVID-19 | ||
| 520 | |a METHODS: N-antigenemia and anti-S1 antibodies were profiled at admission to the emergency department in 146 patients with COVID-19 using the Panbio® antigen Rapid Test and the SARS-CoV-2 immunoglobulin G II Quant/SARS-CoV-2 immunoglobulin G assay from Abbott. A multivariable analysis was used to evaluate the impact of these factors on hospitalization | ||
| 520 | |a RESULTS: Patients with a positive N-antigen test in plasma and anti-S1 levels <2821 arbitrary units/mL needed hospitalization more frequently (20 of 23, 87%). A total of 20 of 71 (28.2%) of those showing a negative N-antigen test and anti-S1 ≥2821 arbitrary units/mL were hospitalized for 18 of 52 (34.6%) of the patients with only one of these conditions. Patients with a positive N-antigen test and low antibody levels showed an odds ratio, 95% confidence interval, and P-value for hospitalization of 18.21, 2.74-121.18, and 0.003, respectively, and exhibited the highest mortality (30.4%) | ||
| 520 | |a CONCLUSIONS: Simultaneous profiling of a rapid N-antigen test in plasma and anti-S1 levels could help to early identify patients with COVID-19 needing hospitalization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-S1 antibodies | |
| 650 | 4 | |a Antigenemia, Emergency room | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hospitalization | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Postigo, Tamara |e verfasserin |4 aut | |
| 700 | 1 | |a Sanus Ferri, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Domínguez-Gil, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez-Manzanares, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Eiros, Jose María |e verfasserin |4 aut | |
| 700 | 1 | |a Carbajosa Rodríguez, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez Ramon, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Fadrique Millán, Laura N |e verfasserin |4 aut | |
| 700 | 1 | |a Vaquero-Roncero, Luis Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban-Velasco, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro-Matías, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Barbé, Ferran |e verfasserin |4 aut | |
| 700 | 1 | |a Bermejo-Martin, Jesús F |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Izquierdo, Raul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 140(2024) vom: 10. Feb., Seite 132-135 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:140 |g year:2024 |g day:10 |g month:02 |g pages:132-135 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2024.01.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 140 |j 2024 |b 10 |c 02 |h 132-135 | ||